STOCK TITAN

Phio Pharmaceuticals director buys 12,000 shares

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

Phio Pharmaceuticals Corp. (PHIO) director David H. Deming reported two direct purchases of common stock totaling 12,000 shares: 9,000 shares on November 12, 2026, at $0.8136 per share, and 3,000 shares on November 13, 2026, at $0.8334 per share. Each transaction is identified as direct ownership.

Insider Deming David H
Role Director
Bought 12,000 shs ($10K)
Increase in Position 24.1%
Type Security Shares Price Value
Purchase Common Stock, $.0001 par value F1 3,000 $0.8334 $3K
Purchase Common Stock, $.0001 par value F1 9,000 $0.8136 $7K
Holdings After Transaction: Common Stock, $.0001 par value — 61,800 shares (Direct)
Holdings Before and After: Common Stock, $.0001 par value, 49,800 to 61,800 shares (Direct)
Other Insiders: 2 other insiders reported open-market purchases of this stock in the 30 days up to this filing.
Footnotes (1)
  1. F1. Includes shares of common stock underlying unvested restricted stock units.
Shares purchased 9,000 shares David H. Deming, November 12, 2026
Purchase price $0.8136 per share David H. Deming, November 12, 2026
Shares purchased 3,000 shares David H. Deming, November 13, 2026
Purchase price $0.8334 per share David H. Deming, November 13, 2026
Shares purchased across two transactions 12,000 shares David H. Deming, November 12 and November 13, 2026
unvested restricted stock units technical
"underlying unvested restricted stock units"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many PHIO shares did director David H. Deming buy, and at what prices?

David H. Deming, a director, bought 12,000 shares of PHIO common stock: 9,000 shares on November 12, 2026, at $0.8136 per share and 3,000 shares on November 13, 2026, at $0.8334 per share. No Rule 10b5-1 plan is reported.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Deming David H

(Last)(First)(Middle)
C/O PHIO PHARMACEUTICALS CORP
411 SWEDELAND RD., STE 23-1080

(Street)
KING OF PRUSSIA PENNSYLVANIA 19406

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Phio Pharmaceuticals Corp. [ PHIO ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/12/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock, $.0001 par value11/12/2026P9,000A$0.813658,800(1)D
Common Stock, $.0001 par value11/13/2026P3,000A$0.833461,800(1)D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Includes shares of common stock underlying unvested restricted stock units.
/s/ Lisa C. Carson, Attorney-in-fact11/16/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading